GlassScriptPhysician profile
Vivian G Hasbrook
NPI 1225101215
$11,792.10
in general payments reported to CMS, 2019-2025
22 companies · $2,328 in 2025
The $2,328 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $744 · 2021: $1,716 · 2022: $2,043 · 2023: $2,093 · 2024: $2,129 · 2025: $2,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,550.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,340.64 | 2020-2025 | Austedo Xr, Uzedy, Austedo |
| Janssen Pharmaceuticals, INC | $1,929.35 | 2019-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $1,705.52 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Abbvie INC. | $1,468.58 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $963.92 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $756.41 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Indivior INC. | $466.07 | 2019-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $454.56 | 2020-2025 | Fanapt |
| Lundbeck LLC | $429.95 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $345.56 | 2024-2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $197.58 | 2021-2022 | |
| Allergan, INC. | $181.38 | 2020 | |
| Neurocrine Biosciences, INC. | $161.55 | 2019-2025 | |
| Novo Nordisk INC | $116.15 | 2022 | |
| Noven Pharmaceuticals, INC. | $107.59 | 2024 | Xelstrym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $60.26 | 2019-2020 | |
| Axsome Therapeutics, INC. | $24.80 | 2023 | Auvelity |
| Eisai INC. | $19.54 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.09 | 2025 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.87 | 2025 | |
| Bioxcel Therapeutics, INC. | $15.06 | 2024 | Igalmi |
| Noven Therapeutics, LLC | $13.67 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivian Hasbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.